Hepatitis D revival

Liver International

Volumn 31, Issue SUPPL. 1, 2011, Pages 140-144

  Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

HDV; Hepatitis delta; Interferon alpha; Natural history

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; CLEVUDINE; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ARTICLE; CANCER RISK; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HEPATITIS DELTA VIRUS; HUMAN; IMMUNOPATHOGENESIS; LIVER CELL CARCINOMA; MIXED INFECTION; NONHUMAN;

ANTIVIRAL AGENTS; HEPATITIS D; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS;

EID: 78650818831     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02408.x     Document Type: Article

References (57)

1. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18: 997-1003.
2. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.
3. Rizzetto M, Shih JW, Gocke DJ, et al. Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet 1979; 2: 986-90.
4. Rizzetto M, Hoyer B, Canese MG, et al. delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci USA 1980; 77: 6124-8.
5. Taylor JM. Hepatitis delta virus. Virology 2006; 344: 71-6.
6. Radjef N, Gordien E, Ivaniushina V, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004; 78: 2537-44.
7. Su CW, Huang YH, Huo TI, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-35.
8. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
9. Cornberg M, Protzer U, Dollinger MM, et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-) infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 2007; 45: 525-74.
10. Mederacke I, Bremer B, Heidrich B, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48: 2022-9.
11. Zachou K, Yurdaydin C, Dienes HR, et al. Significance of HDV-RNA and HBsAg levels in D hepatitis: first data of the HEP-NET/International HDV Intervention Trial. Liver Int. 2010; 30: 430-7.
12. Hadziyannis SJ. Review: hepatitis delta. J Gastroenterol Hepatol 1997; 12: 289-98.
13. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection - not a vanishing disease in Europe! Hepatology 2007; 45: 1331-2.
14. Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology 2000; 32 (Part 1): 824-7.
15. Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010; 202: 845-52.
16. Erhardt A, Knuth R, Sagir A, et al. Socioepidemiological data on hepatitis delta in a German university clinic-increase in patients from Eastern Europe and the former Soviet Union. Z Gastroenterol 2003; 41: 523-6.
17. Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80: 277-82.
18. Le Gal F, Castelnau C, Gault E, et al. Reply to Wedemeyer et al., hepatitis D - not a vanishing disease. Hepatology 2007; 45: 1332-3.
19. Mele A, Mariano A, Tosti ME, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis 2007; 44: e17-24.
20. Nisini R, Paroli M, Accapezzato D, et al. Human CD4+T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 1997; 71: 2241-51.
21. Aslan N, Yurdaydin C, Wiegand J, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepatol 2006; 13: 505-14.
22. Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis 2010; 28: 133-8.
23. Pugnale P, Pazienza V, Guilloux K, Negro F. Hepatitis delta virus inhibits alpha interferon signaling. Hepatology 2009; 49: 398-406.
24. Wedemeyer H, Tillmann HL, Tegtmeyer B, et al. Infection with multiple hepatitis viruses: evidence for suppression of HCV replication by HDV and HBV. Hepatology 2001; 34: 223.
25. Deterding K, Pothakamuri SV, Schlaphoff V, et al. Clearance of Chronic HCV Infection During Acute D hepatitis. Infection 2009; 37: 159-62.
26. Heidrich B, Deterding K, Tillman HL, et al. Virological and Clinical characteristics of D hepatitis in Central Europe. J Viral Hepat. 2009; 16: 883-94.
27. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43: 100-7.
28. Rizzetto M. Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg 2000; 63: 221-4.
29. Dienes HP, Purcell RH, Popper H, Ponzetto A. The significance of infections with two types of viral hepatitis demonstrated by histologic features in chimpanzees. J Hepatol 1990; 10: 77-84.
30. Casey JL, Niro GA, Engle RE, et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis 1996; 174: 920-6.
31. Flodgren E, Bengtsson S, Knutsson M, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol 2000; 38: 3311-6.
32. Tsatsralt-Od B, Takahashi M, Endo K, et al. Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia. J Med Virol 2006; 78: 542-50.
33. Fattovich G, Boscaro S, Noventa F, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987; 155: 931-5.
34. Uzunalimoglu O, Yurdaydin C, Cetinkaya H, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001; 46: 1022-8.
35. Wedemeyer H, Yurdaydin CD. Hepatitis. In: Tillman HL, ed. Handbuch Hepatitis B: Diagnostik, Verlauf, Therapie. Bremen: Uni-Med, 2007; 96-103.
36. Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34: 404-10.
37. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-10.
38. Yurdaydin C. D hepatitis in Turkey: decreasing but not vanishing and still of concern. Turk J Gastroenterol 2006; 17: 74-5.
39. Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for D hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008; 28: 494-8.
40. Romeo R, Del NE, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-38.
41. Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic D hepatitis in Italy: a long-term cohort study. J Hepatol 2010; 53: 834-40.
42. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepatol 2008; 15: 165-72.
43. Sheng WH, Hung CC, Kao JH, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44: 988-95.
44. Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir treatment of chronic D hepatitis. J Hepatol 2002; 37: 266-71.
45. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepatol 2005; 12: 2-9.
46. Wedemeyer H, Yurdaydin C, Dalekos G, et al. 72 week data of the HIDIT-1 trial: a multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic D hepatitis. J Hepatol 2007; 46: 4.
47. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44: 713-20.
48. Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon therapy with or without ribavirin in chronic D hepatitis. Antivir Ther 2005; 10: 721-6.
49. Garripoli A, Di MV, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14: 154-7.
50. Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther 2008; 13: 97-102.
51. Casey J, Cote PJ, Toshkov IA, et al. Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks. Antimicrob Agents Chemother 2005; 49: 4396-9.
52. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88-94.
53. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-9.
54. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-10.
55. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-35.
56. Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112: 407-14.
57. Mederacke I, Wedemeyer H. Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges? Ann Hepatol 2009; 8: 166-8.